Postmeal triglyceridemia and variability of HbA1c and postmeal glycemia were predictors of annual decline in estimated glomerular filtration rate in type 2 diabetic patients with different stages of nephropathy

Ayaka Tsuboi1,2, Akiko Takenouchi3, Miki Kurata1,3, Keisuke Fukuo1,3 and Tsutomu Kazumi1,4*

Abstract

Background: This study examined associations of annual glycemic variability and postprandial dysmetabolism with annual decline in estimated glomerular filtration rate (eGFR) in type 2 diabetic patients with different stages of nephropathy.

Methods: Intrapersonal mean and coefficient of variation (CV) of HbA1c, fasting and postmeal concentrations of plasma glucose (FPG and PMPG, respectively) and serum triglycerides (FTG and PMTG, respectively) during the first 12 months after enrollment were calculated in a cohort of 168 type 2 diabetic patients: 53 with optimal albumin/creatinine ratio (ACR < 10 mg/g), 62 with high normal ACR (10–29 mg/g) and 53 with elevated ACR (≧30 mg/g). Annual changes in eGFR were computed using 52 (median) creatinine measurements obtained over a median follow-up of 6.0 years. Multivariate linear regressions assessed the independent correlates of changes in eGFR.

Results: Kidney function declined faster in patients with high normal and elevated ACR (−1.47 and −2.01 ml/min/1.73 m²/year, respectively) compared to patients with optimal ACR (0.08 ml/min/1.73 m²/year, p < 0.05). In patients with high normal ACR, age (standardized β = -0.30, p = 0.01), CV-HbA1c (standardized β = -0.66, p < 0.001) and CV-PMPG (standardized β = -0.27, p = 0.01) was associated with annual eGFR decline independently of mean HbA1c and PMPG, sex, BMI, waist circumference, diabetes duration and therapy, means and CVs of FPG and systolic blood pressure, baseline eGFR, log ACR and uses of anti-hypertensive medications (R² = 0.47). In patients with elevated ACR, PMTG (standardized β = -0.408, p = 0.007) was associated with annual eGFR decline (R² = 0.15).

Conclusions: Consistency of glycemic control and management of postprandial glycemia and lipidemia are important to preserve kidney function in type 2 diabetic patients.

Keywords: Postmeal glucose, HbA1c, Coefficient of variation, Postmeal triglycerides, Kidney function, eGFR
Background

The incidence and prevalence of chronic kidney disease are increasing [1], and it has been recognized as a medical, social, and economic problem worldwide. A mild decline of kidney function increases the risk of cardiovascular disease in the general population [2]. Therefore, the early detection and aggressive modification of risk factors for the decline of kidney function are important. Aging, hypertension, and diabetes mellitus are the most common risk factors for the development of chronic kidney disease [3, 4]. In addition to hypertension and diabetes, dyslipidemia has an important role in the progression of kidney disease in patients with diabetes [5]. Longitudinal studies have found an association between fasting serum triglycerides (FTG) and the development of chronic renal insufficiency [6–9]. However, we are not aware of report that examined associations of postmeal TG (PMTG) with changes in kidney function despite the fact that the vasculature is commonly exposed to prolonged and exaggerated postprandial triglyceridemia, especially in type 2 diabetic patients [10].

There is emerging interest to examine the influence of glycemic and BP variance in diabetic vascular complications [11, 12]. Recently, we have shown direct association of HbA1c variability and albuminuria with kidney function decline in type 2 diabetic patients [13]. We, therefore, asked the question whether glycemic variability, fasting and postmeal plasma glucose (FPG) might directly associated with annual decline in estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes with different stages of nephropathy.

Methods

The setting for this observational study was the same as previously reported [13]. Study protocol was consistent with the Japanese Government's Ethical Guidelines Regarding Epidemiological Studies in accordance with the Declaration of Helsinki. Patients with hepatitis B surface antigen or antibodies against hepatitis C virus were excluded. Those who had aspartate aminotransferase and alanine aminotransferase of 100 U/L or greater, serum creatinine $\geq 2.0$ mg/dl were excluded as well. We examined a cohort of 168 patients with type 2 diabetes in whom 153 patients (91%) had 12 monthly visits with blood samplings [13]. They had been regularly attending the clinic in 2004 and 2005. They were enrolled in the study at the first visit in 2005 and followed up for the subsequent at least 24 months through December 31, 2012 to assess kidney function with a median follow-up of 6.0 years (interquartile range; 4.1–6.5 years). In the 153 patients, blood was withdrawn on 2 occasions; at 2 h after breakfast taken at home and after an overnight fasting. This was done every other month. In the remaining 15 patients, blood was obtained after an overnight fasting.

For each subject on each monthly visit, waist circumference, weight and BP were measured by registered nurses. Plasma glucose (PG) was determined by the glucose oxidase method using an autoanalyzer (Glucoroder MAX, A&T, Yokohama, Japan). Serum lipids and lipoproteins, creatinine, hepatic enzymes, uric acid and other blood tests were measured by standard methods using an autoanalyzer (H7600, Hitachi, Tokyo, Japan). HbA1C values were determined by high performance liquid chromatography (HLC723-G7, Tosoh, Tokyo, Japan). Urinary albumin was measured once during the first 3–4 months after enrollment in random urine samples using a turbidimetric immunoassay and expressed as albumin/creatinine ratio (ACR). Serum and urinary creatinine were measured enzymatically and estimated glomerular filtration rate (eGFR) was determined using the equation recommended by the Japanese Society for Nephrology [14].

Microalbuminuria was defined as ACR between 30 and 299 mg/g [15]. The recommended normal range was further subdivided into high normal ACR (10–29 mg/g) and optimal ACR (<10 mg/g) [16]. Because relatively few participants (n = 6) had macroalbuminuria (ACR $\geq$300 mg/g), these participants were grouped with those who had microalbuminuria and were termed as elevated ACR.

Intrapersonal mean and coefficient of variation (CV) of HbA1c, fasting and postmeal plasma glucose (FPG and PMPG, respectively) and serum triglycerides (FTG and PMTG, respectively) taken during the first 12 months after enrollment were calculated; 153 patients (91%) had 12 measurements of HbA1c and systolic BP, and 6 measurements of FPG, PMPG, FTG and PMTG, respectively. Linear regression was used to estimate changes in eGFR using a median of 52 creatinine measurements (interquartile range; 31–60) over 6.0 years of follow-up in each patient.

Data were presented as mean ± SE unless otherwise stated. Differences between 2 groups were analyzed by t test and frequencies of conditions by Chi-square tests. Differences among 3 groups were analyzed using analysis of variance and then Bonferroni’s multiple comparison procedure was done. Correlations of annual eGFR decline were evaluated by Pearson correlation analysis. Multiple linear regression analyses were performed to further identify the most significant variables contributing to annual eGFR decline. Potential confounders were forced into the model and standardized $\beta$ coefficients were calculated. A two-tailed $P < 0.05$ was considered statistically significant. All calculations were performed with SPSS system 15.0 (SPSS Inc., Chicago, IL).
Results
As previously reported [13], patients had relatively good glycemic, lipid and BP control. Baseline means of eGFR were means of 2–4 measurements during the first 3–4 months after enrollment, and averaged 76 ± 16 ml/min/1.73 m². Changes in eGFR were linear and averaged −1.05 ± 3.39 ml/min/1.73 m² per year. At baseline, 27 (16.0%) of 168 patients had eGFR < 60 ml/min/1.73 m² and 53, 62 and 53 patients had optimal, high normal and elevated ACR (microalbuminuria 47, macroalbuminuria 6), respectively.

Patients with elevated compared to optimal ACR were older, had higher mean HbA1c, FPG and PMPG (Table 1). Patients with elevated ACR had higher FTG and systolic BP and lower HDL cholesterol. In patients with high normal and elevated ACR eGFR decreased whereas eGFR did not change in patients with optimal ACR. There was no difference in baseline eGFR among 3 groups and other variables.

In patients with high normal ACR, annual eGFR change was inversely associated with CV-HbA1c, CV-FPG and CV-PMPG but not with means of the 3 glycemic variables (Table 2). However, annual eGFR decline did not show significant associations with age, sex, duration of diabetes, baseline eGFR, treatment for diabetes, lipids and BP variables. Multiple linear regression analysis revealed that age (standardized $\beta$ = -0.30, $p = 0.01$), CV-HbA1c (standardized $\beta$ = -0.66, $p < 0.001$) (Fig. 1a) and CV-PMPG (standardized $\beta$ = -0.27, $p = 0.01$) (Fig. 1b) was associated with annual eGFR decline independently of mean HbA1c and PMPG, sex, BMI, waist circumference, diabetes duration and therapy, means and CVs of FPG and systolic blood pressure, baseline eGFR, log ACR and uses of anti-hypertensive medications ($R^2 = 0.47$).

In patients with elevated ACR, annual eGFR decline was inversely associated with CV-HbA1c, PMTG and urinary ACR and positively with treatment of hypertension and systolic BP (Table 2). However, annual eGFR decline did not show significant association with any other variables. Multiple linear regression analysis revealed that PMTG (standardized $\beta$ = -0.408, $p = 0.007$) (Fig. 1c) was associated with annual eGFR decline independently of CV-HbA1c, age, sex, BMI, waist circumference, duration and treatment of diabetes, means and CVs of HbA1c, FPG and PMPG, FTG, baseline eGFR, log ACR and uses of anti-hypertensive and lipid-lowering medications ($R^2 = 0.15$).

There was no significant association between eGFR changes and any variables studied in patients with optimal ACR (Table 2).
also the first to demonstrate direct associations of PMTG with annual decline in kidney function in type 2 diabetic patients with elevated ACR. These associations were independent of mean HbA1c and PMPG, FTG and known predictors of GFR decline [17]. The current finding that kidney function decline was faster in patients with high normal compared to optimal ACR has confirmed previous studies that urinary albumin, even in the microalbuminuric range, is a predictor of renal function impairment [17–20].

As mentioned earlier, longitudinal studies have found an association between FTG and renal replacement therapy in type 2 diabetic patients [6], GFR decline in patients with chronic glomerulonephritis [7], a rise in serum creatinine of 0.4 mg/dL or greater in the general population [8] and development of renal impairment in type 2 diabetic patients [9]. In the UK prospective Diabetes Study [21], high levels of FTG were an independent risk factor of micro- and macro-albuminuria. The present study is the first to demonstrate that PMTG but not FTG was associated with annual GFR decline in type 2 diabetic patients with nephropathy (elevated ACR), CV of HbA1c, which showed strong association in univariate analysis, did not emerge as an independent predictor of annual eGFR decline in patients with elevated ACR, although it was independently associated with annual eGFR decline in the entire 168 patients as recently reported [13].

Recent meta-analyses [11, 22] indicated that higher HbA1C variability was independently associated with higher risk of renal disease in both type 1 and 2 diabetes patients. Our previous study was the first to show a direct association between annual HbA1c variability and kidney function decline and demonstrated stronger association in type 2 diabetic patients with elevated ACR than in patients with normoalbuminuria [13]. In the present study, patients with normoalbuminuria were divided into 2 groups: those with optimal and high normal ACR and 2 groups were analyzed separately. Annual eGFR decline was independently associated with CV of HbA1c in patients with high normal ACR but not in patients with optimal and elevated ACR.

In a recent systematic review [23], only 2 studies assessed the association of postprandial glucose with retinopathy [24, 25] but no report with diabetic kidney disease. The current study is the first to demonstrate direct associations of annual variation in PMPG but not mean PMPG with annual decline in eGFR in type 2 diabetic patients with high normal ACR. We are aware of only 1 prospective study [26] assessing the relationship between variation in FPG and risk of kidney disease in type 2 diabetic patients. Lin et al. [26] reported that annual variation in HbA1c and FPG was independently associated with risk of diabetic nephropathy (eGFR < 60 mL/min/1.73 m²). Among 4399 patients with type 2 diabetes in the intensive group of the ADVANCE trial [27], SD of FPG and HbA1c independently predicted future combined microvascular events (nephropathy or retinopathy).

Several mechanisms including oxidative stress and inflammation may be involved in the association between glycemic variability and outcomes as recently discussed in detail [11]. Current findings of independent associations of PMTG and CV-PMPG with annual decline in kidney function in type 2 diabetic patients may be in line with the observation of an independent effect of

### Table 2: Correlation coefficients of annual changes in estimated glomerular filtration rates in type 2 diabetic patients with optimal, high normal and elevated urinary albumin/creatinine ratio (ACR)

| ACR status | Optimal (ACR < 10) | High normal (ACR 10–20) | Elevated (ACR ≥30) |
|------------|--------------------|-------------------------|-------------------|
| Male sex (n, %) | −0.163 | −0.008 | 0.207 |
| Smokers (n, %) | −0.182 | −0.226 | −0.022 |
| Age (years) | −0.115 | −0.028 | 0.175 |
| BMI (kg/m²) | −0.232 | 0.094 | −0.110 |
| Waist circumference (cm) | −0.277 | −0.030 | −0.099 |
| Duration of diabetes (years) | −0.242 | −0.170 | 0.081 |
| Treatment of diabetes: diet/OHA/insulin (%) | −0.133 | −0.173 | −0.140 |
| Hypertension: CCB/RASi/diuretics (%) | −0.286 | −0.134 | 0.292* |
| HbA1c (%) | −0.094 | −0.097 | 0.045 |
| Fasting PG (mg/dl) | −0.096 | −0.148 | 0.113 |
| Post-breakfast PG (mg/dl) | −0.083 | −0.080 | 0.086 |
| CV-HbA1c (%) | 0.164 | −0.509*** | −0.400** |
| CV-Fasting PG (%) | −0.050 | −0.424** | −0.233 |
| CV-Post-breakfast PG (%) | −0.067 | −0.330* | −0.056 |
| Total cholesterol (mg/dl) | 0.103 | −0.067 | 0.114 |
| LDL cholesterol (mg/dl) | 0.000 | −0.094 | 0.083 |
| HDL cholesterol (mg/dl) | 0.130 | −0.009 | 0.170 |
| Fasting TG (mg/dl) | −0.091 | 0.013 | −0.257 |
| Post-breakfast TG (mg/dl) | −0.054 | 0.014 | −0.343* |
| Serum creatinine (mg/dl) | 0.029 | 0.006 | −0.132 |
| eGFR (ml/min/1.73 m²) | 0.013 | −0.128 | −0.034 |
| ΔeGFR (ml/min/1.73 m²/year) | 1.000 | 1.000 | 1.000 |
| Uric acid (mg/dl) | −0.040 | −0.082 | −0.080 |
| Systolic BP (mmHg) | −0.164 | −0.109 | 0.302* |
| CV-Systolic BP (%) | −0.107 | −0.156 | 0.064 |
| Diastolic BP (mmHg) | −0.085 | −0.002 | 0.146 |
| Urinary ACR (mg/g) | −0.012 | −0.157 | −0.281* |
| log ACR | −0.077 | −0.169 | −0.034 |

Abbreviations are the same as in Table 1: *: p < 0.05, **: p < 0.01, ***: p < 0.001
postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation in both diabetic and normal subjects [28].

Type 2 diabetic patients with high normal and elevated ACR in the present study had annual eGFR decline (−1.47 and −2.01 ml/min/1.73 m² per year, respectively) which was comparable to non-diabetic Japanese patients with early-stage chronic kidney disease (eGFR > 60 ml/min/1.73 m²) (−1.64 ml/min/1.73 m² per year) [29]. Further, annual eGFR decline of our patients was slower than the rate found in Japanese type 2 diabetic patients without clinical albuminuria (−2.94 ml/min/1.73 m² per year) [30] despite comparable baseline eGFR. These findings may be due in part to the fact that our patients had better glycemic (mean HbA1c; 7.0–7.3 vs. 8.4%) and BP (127–132 vs. 135 mmHg) control. Slower eGFR decline associated with better diabetic control in our patients may be related to failure to detect association between mean HbA1c and annual eGFR decline in the present study.

The strength of the current study is that we used 12-month period when mean HbA1c and HbA1c variability were calculated from 12 measurements in 91% participants. Postmeal TG were measured after breakfast eaten at home: in real-life conditions. In addition, serum creatinine and hence eGFR during follow-up period were measured much more frequently than in previous studies as mentioned elsewhere [13]. This could contribute to the reliability of changes in kidney function. Such a testing frequency is routine in clinical settings in Japan. However, frequent measures of HbA1c may artificially inflate precision and decrease standard deviation, which may impact the results. Finally, BP control and variability and postprandial TG also have been taken into accounted. Major limitations are that study participants were small in number and from a single clinic in Japan.

However, the characteristics of our study participants are similar to those reported in a previous large-scale study in Japan [31]. Another limitation was that urinary ACR was measured once in a random urine sample. Since the albumin excretion variability is too high, classification of patients according to single measurement of ACR may be unreliable.

Conclusions

The current study has demonstrated that predictors of annual decline in kidney function differed in type 2 diabetic patients with different stages of nephropathy. These findings suggest that more attention should be paid by clinicians in diabetes control, avoiding excessive oscillations in blood glucose levels in type 2 diabetic patients with high normal ACR. In patients with ACR ≥ 30 mg/g, management of postmeal TG may be important because normotriglyceridemic patients with type 2 diabetes and microalbuminuria have an almost 3-fold higher postprandial triglyceridemia than patients without microalbuminuria after ingestion of a mixed test meal [32]. Further studies are needed to confirm the association in other ethnic groups with more patients.

Abbreviations

ACR: Albumin/creatinine ratio; BP: Blood pressure; CV: Coefficient of variation; eGFR: estimated glomerular filtration rate; FPG: Fasting plasma glucose; FTG: Fasting serum triglycerides; PMPG: Post-meal plasma glucose; PMTG: Post-meal serum triglycerides.

Acknowledgments

The authors are indebted to all the participants for their dedicated and conscientious collaboration. We also thank Dr. Takeo Sadamitsu, MS. Ayako Kameyama and Ms. Atsuko Muranaka, Sadamitsu Hospital, for their help.

Funding

None.

Availability of data and materials

Please contact author for data requests.
Authors' contributions
AYT, AKT and MK have made substantial contributions to acquisition, analysis and interpretation of data. KF has been involved in drafting the manuscript. TK has been involved in revising it critically for important intellectual content; have given final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Study protocol was consistent with the Japanese Government's Ethical Guidelines Regarding Epidemiological Studies in accordance with the Declaration of Helsinki.

Author details
1Research Institute for Nutrition Sciences, Mukogawa Women’s University, 6-46, Ikeyabuchi-cho, Nishinomiya, Hyogo 663-8558, Japan. 2Department of Nutrition, Osaka City Juso Hospital, Osaka 532-0034, Japan. 3Department of Food Sciences and Nutrition, School of Human Environmental Sciences, Mukogawa Women’s University, 6-46, Ikeyabuchi-cho, Nishinomiya, Hyogo 663-8558, Japan. 4Diabetes Division, Kohnan Kakogawa Hospital, Kakogawa, Hyogo 675-0005, Japan.

Received: 26 August 2016 Accepted: 4 December 2016

Published online: 11 January 2017

References
1. Hallan SI, Coresh J, Astor RC, Asberg A, Powe NR, Ronnundstad S, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006;17:2275–84.
2. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13:745–53.
3. Shulman NB, Ford CE, Hall WD, Blafox MD, Simon D, Langford HG, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 1989;13(Suppl):180–93.
4. Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71:159–66.
5. Rutledge JC, Ng KF, Aung HH, Wilson DW. Role of triglyceride-rich lipoproteins in diabetic nephropathy. Nat Rev Nephrol. 2010;6:361–70.
6. Cuscic M, Chew EY, Hoogwerf B, Agrón E, Wu L, Lindley A, et al. Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26. Kidney Int. 2004;66:1173–9.
7. Samuelsson O, Muler H, Knight-Gibson C, Attman PO, Kron B, Larsson R, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant. 1997;12:1908–15.
8. Muntner P, Coresh J, Smith JC, Edfeldt J, Klaj M. Plasma lipids and risk of developing renal dysfunction: the Atherosclerosis Risk in Communities Study. Kidney Int. 2000;58:293–301.
9. Afghahi H, Cederholm J, Elsson B, Zethelius B, Gudbjörnsdottir S, Haldar H, et al. Risk factors for albuminuria and renal impairment in type 2 diabetes—the Swedish National Diabetes Register (NDR). Nephrol Dial Transplant. 2011;26:1236–43.
10. Anastromas S, Terzi AD, Toussoulis D, Koulouri S. Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus. Int J Cardiol. 2008;126:12–13.
11. Gorst C, Kwok CS, Aslam S, Buchan I, Kontopantelis E, Myint PK, et al. Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis. Diabetes Care. 2015;38:2354–69.
12. Parati G, Liu X, Ochoa JE. Clinical relevance of visit-to-visit blood pressure variability: impact on renal outcomes. J Hum Hypertens. 2014;28:403–9.
13. Takenouchi A, Tsuiboi A, Terazawa-Watanabe M, Kurata M, Fukuo K, Kazumi T. Direct association of visit-to-visit HbA1c variation with annual decline in estimated glomerular filtration rate in patients with type 2 diabetes. J Diabetes Metab Disord. 2015;14:69.
14. Matsu S, Imai E, Hori M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
15. American Diabetes Association. (9) Microvascular complications and foot care. Diabetes Care. 2013;36(Suppl 1): S58–66.
16. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17–28.
17. Yokoyama H, Kanno S, Takahashi S, Yamada D, Honjo J, Saito K, et al. Risks for glomerular filtration rate decline in association with progression of albuminuria in type 2 diabetes. Nephrol Dial Transplant. 2011;26:2924–30.
18. Verhave JC, Gansevoort RT, Hillegé HL, Bakker SJ, De Zeeuw D, de Jong PE, et al. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int Suppl. 2004;92:S18–21.
19. Zoppini G, Targer H, Chonchol M, Orfèdta V, Negri C, Stoico V, et al. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol. 2012;7:901–8.
20. Babazono T, Nyumura I, Toya K, Hayashi T, Ohta M, Suzuki K, et al. Higher levels of urinary albumin excretion within the normal range predict faster decline in glomerular filtration rate in diabetic patients. Diabetes Care. 2009;32:1518–20.
21. Retnakaran R, Cull CA, Thorne KJ, Adler AI, Holman RR, UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006;55:1802–9.
22. Cheng D, Fei Y, Liu Y, Li J, Xue Q, Wang X, et al. HbA1C variability and the risk of renal status progression in Diabetes Mellitus: a meta-analysis. PLoS One. 2014;9:e115509.
23. Mannucci E, Monami M, Lamanna C, Adalsteinsson JE. Post-prandial glucose and diabetic complications: systematic review of observational studies. Acta Diabetol. 2012;49:307–14.
24. Shiraiwa T, Kaneto H, Miyazaka T, Kato K, Yamamoto K, Kawashima A, et al. Postprandial hyperglycemia is a better predictor of the progression of diabetic retinopathy than HbA1c in Japanese type 2 diabetic patients. Diabetes Care. 2005;28:2806–7.
25. Liu QZ, Pettitt DJ, Hanson RL, Charles MA, Klein R, Bennett PH, et al. Glycated haemoglobin, plasma glucose and diabetic retinopathy: cross sectional and prospective analyses. Diabetologia. 1993;36:28–32.
26. Lin CC, Chen CC, Chen FN, Li CI, Liu CS, Lin WW, et al. Risks of diabetic nephropathy with variation in hemoglobin A1c and fasting plasma glucose. Am J Med. 2013;126:1017.e1-10.
27. Hirakawa Y, Atima H, Zouangs S, Ninomiya T, Cooper M, Hamet P, et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014;37:2359–65.
28. Cerello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, et al. Evidence for an independent and cumulative effect of postprandial hypertriglycerideremia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation. 2002;106:1211–8.
29. Yoshida T, Takte T, Shintoh S, Tsukada M, Sugihara I, Irabashi M, et al. Risk factors for progression in patients with early-stage chronic kidney disease in the Japanese population. Intern Med. 2008;47:1789–94.
30. Babazono T, Hanai K, Suzuki K, Kuchi Y, Inoue A, Tanaka M, et al. Lower haemoglobin level and subsequent decline in kidney function in type 2 diabetic adults without clinical albuminuria. Diabetologia. 2006;49:1387–93.
31. Sone H, Tanaka S, Imamura S, Tanaka S, Oida K, Yamashita Y, et al. Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicenter randomized controlled trial (the Japan Diabetes Complications Study). Diabetologia. 2010;53:419–28.
32. Tentolouris N, Stylianou A, Lourida E, Perrea D, Kyriaki D, Papavasiliou EC, et al. Long postprandial triglycerideremia in patients with type 2 diabetes and microalbuminuria. J Lipid Res. 2007;48:218–25.